Submission of Audited Annual Standalone Financial Statements 2024-25 along with Auditors'' Report thereon
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Denis Chem Lab, which makes intravenous/transfusion solutions, reported FY25 revenue from operations of Rs. 17,329.97 lakh, up modestly about 3.3% from Rs. 16,782.20 lakh in FY24. However, profit after tax fell sharply to Rs. 807.58 lakh from Rs. 1,115.58 lakh, a drop of around 28%, mainly because total expenses grew about 6.8% while revenue grew only 3.3%, squeezing margins. Q4 alone was weak: PAT of Rs. 70.75 lakh versus Rs. 272.92 lakh a year earlier. The board has recommended a final dividend of Rs. 1.50 per share (15%) subject to shareholder approval. The auditor (Shah & Shah Associates) issued an unmodified (clean) opinion. A notable flag: the company received a Rs. 12.09 crore GST/excise demand order (relating to May 2000–June 2017) and has appealed to CESTAT, treating it as a contingent liability.
Positive signals: clean audit, low debt (no loan defaults), steady revenue growth, and a dividend payout. Negative signals: a sharp fall in profits, margin compression, and a sizable Rs. 12.09 crore tax dispute that could hurt if the appeal fails. For shareholders, the result is mixed — operations are stable but profitability has weakened and a material tax overhang remains.